C-suite reality: how to resource your next product when it competes with your lead
This article was originally published in Scrip
A bovine extracted product, or a human recombinant one? The choice isn't that obvious, especially if neither product has human proof of concept and the bovine product is less clinically advanced. This is the real dilemma that AM-Pharma faced in 2011, as chief executive officer Erik van den Berg explains to Mike Ward. In the end, AM raised nearly €30m and was able to forge ahead with the market's preferred product. But the case illustrates that for smaller companies, strategy decides between the best available options, not between ideal ones.